Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

8.43
-0.2100-2.43%
Volume:66.61K
Turnover:558.56K
Market Cap:430.00M
PE:-2.25
High:8.58
Open:8.35
Low:8.23
Close:8.64
52wk High:12.34
52wk Low:2.24
Shares:51.01M
Float Shares:36.78M
Volume Ratio:0.77
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7446
EPS(LYR):-2.9821
ROE:-45.38%
ROA:-27.64%
PB:1.17
PE(LYR):-2.83

Loading ...

4D Molecular Therapeutics Q3 EPS $(1.01) Misses $(0.98) Estimate, Sales $90.000K Miss $287.857K Estimate

Benzinga
·
Nov 10, 2025

BRIEF-4D Molecular Therapeutics Q3 Net Income USD -56.876 Million Vs. IBES Estimate USD -56.2 Million

Reuters
·
Nov 10, 2025

4D Molecular Therapeutics Q3 Revenue USD 90 Thousand VS. Ibes Estimate USD 287.9 Thousand

THOMSON REUTERS
·
Nov 10, 2025

Press Release: 4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Dow Jones
·
Nov 10, 2025

4D Molecular Therapeutics Inc expected to post a loss of 98 cents a share - Earnings Preview

Reuters
·
Nov 08, 2025

Bullish Outlook on 4D Molecular Therapeutics’ 4D-150: Promising Long-term Efficacy, Safety, and Financial Strength Justify Buy Rating

TIPRANKS
·
Nov 07, 2025

Morgan Stanley Upgrades 4D Molecular Therapeutics to Equalweight From Underweight

MT Newswires Live
·
Nov 07, 2025

4D Molecular Therapeutics to Join Jefferies London Healthcare Conference

Reuters
·
Nov 07, 2025

4D Molecular Therapeutics Inc - Shares Priced at $10.51 Each, Pre-Funded Warrants at $10.5099 Each

THOMSON REUTERS
·
Nov 06, 2025

4D Molecular Therapeutics Reports Positive Long-Term Data for 4D-150 in Wet AMD Trial

Reuters
·
Nov 06, 2025

4Dmt Announces Positive Long-Term Data From Phase 1/2 Prism Clinical Trial in Wet Amd Supporting 4D-150’S Potential as a Backbone Therapy With Consistent and Durable Benefit Over Multiple Years

THOMSON REUTERS
·
Nov 06, 2025

4D Molecular Therapeutics Inc - 4D-150 Well Tolerated With No New Safety Issues

THOMSON REUTERS
·
Nov 06, 2025

4D Molecular Therapeutics (FDMT) Receives a Sell from Morgan Stanley

TIPRANKS
·
Nov 04, 2025

4D Molecular Therapeutics Secures $85 Million Upfront in Licensing Deal With Otsuka for 4D-150 in Asia-Pacific

Reuters
·
Oct 31, 2025

4Dmt Announces Exclusive License Agreement With Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

THOMSON REUTERS
·
Oct 31, 2025

4D Molecular Therapeutics Inc - up to $336 Mln in Potential Milestones and Royalties

THOMSON REUTERS
·
Oct 31, 2025

4D Molecular Therapeutics Inc - 4Dmt to Receive $85 Mln Upfront and $50 Mln Cost Sharing

THOMSON REUTERS
·
Oct 31, 2025

4D Molecular Therapeutics Executive Makes Notable Stock Sale

TIPRANKS
·
Oct 28, 2025

4D Molecular Therapeutics (FDMT) Gets a Buy from Bank of America Securities

TIPRANKS
·
Oct 23, 2025

4D Molecular Therapeutics Price Target Maintained With a $26.00/Share by RBC Capital

Dow Jones
·
Oct 21, 2025